Pharmacotherapy

The primary pharmacotherapy treatment for OCD are serotonin reuptake inhibitors (SSRI's) which helped partially with the condition as it is shown improvements in 40 to 60% of OCD patients. A study showed the potential of cortical morphology based on individual structural covariance or ISC. This showed dysfunctional cortical maturation process as a biomarker that protects the clinical treatment response to SSRI based for current therapy success in patients suffering from OCD.



Brain morphology for OCD patients have reported just think of morphological or functional de-arrangements of multiple brain regions, such as the orbitofrontal cortex, anterior cingulate cortex, insula, inferior parietal lobule, precuneous, superior temporal cortex and lingual cortex which collectively constitute the pathopsychological brain circuit of OCD called the"cortico-striato-thalamo-cortical" loop. This study coordinated variations in brain morphological features including cortical surface area or CSA and thickness. This model seeks to understand how some people responded positively to SSRIs rather than others that didn't respond at all. This study recruited 56 medication for the OCD patients who met the diagnostic and statistical manual of mental disorders the fourth edition (DSM IV). Each of them was given a certified psychiatric scored test which measured obsessive-compulsiveness, depression and anxiety to measure the severity of their symptomatology. Using a whole brain anatomy three-dimensional McIntyre station prepared rapid gradient echo, they measured the structural covariance of cortical thickness at the individual level. Out of the data that was recruited they average and calculated the standard deviation of each result. The group was also subdivided into two portions; the nonresponsive group and the responsive group.